Participants with the minor allele C of rs10811661 in CDKN2A/CDKN2B showed a significantly greater reduction in fasting blood glucose ( TT vs TC vs CC : 9.3 % ( 0-20 .0 % ) vs 9.2 % ( 0.9-20 .5 % ) vs 12.7 % ( 5.2-24 .4 % ) , p = 0.008 ) after the initial 4 weeks of treatment independent of age , sex and BMI .